Integral Health Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Integral Health Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.9M	Sell	40,000 -45,000	-53%	-$30.6M	0.99%	30
2026 Q1	$65.7M	Sell	85,000 -20,000	-19%	-$15.3M	3.14%	6
2025 Q4	$81M	Buy	105,000 +55,000	+110%	+$37.4M	4.02%	5
2025 Q3	$28.1M	Hold	50,000	–	–	1.9%	11
2025 Q2	$26.3M	Buy	+50,000	New	+$27.9M	2.4%	10
2024 Q2	–	Sell	-17,000	Closed	-$16.4M	–	97
2024 Q1	$16.4M	Sell	17,000 -8,000	-32%	-$7.61M	1.52%	23
2023 Q4	$22M	Buy	+25,000	New	+$20.6M	2.99%	6
2023 Q2	–	Sell	-3,000	Closed	-$2.47M	–	96
2023 Q1	$2.47M	Buy	+3,000	New	+$2.26M	0.5%	57
2021 Q4	–	Sell	-10,000	Closed	-$6.05M	–	82
2021 Q3	$6.05M	Sell	10,000 -8,500	-46%	-$5.28M	1.74%	20
2021 Q2	$10.3M	Buy	+18,500	New	+$9.37M	2.84%	7
2020 Q3	–	Sell	-12,000	Closed	-$7.48M	–	85
2020 Q2	$7.48M	Buy	+12,000	New	+$6.81M	2.24%	18

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Integral Health Asset Management's REGN Position: Q2 2026 in Review

Integral Health Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 53% in Q2 2026, selling an estimated $30.6M and leaving 40,000 shares worth $24.9M. The position accounts for 0.99% of the portfolio, ranked #30.

Integral Health Asset Management first reported a position in REGN in Q2 2020 and has held it in 11 quarters since. The position peaked at $81M in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Integral Health Asset Management held 40,000 shares of Regeneron Pharmaceuticals worth $24.9M as of Q2 2026.
Integral Health Asset Management sold 45,000 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $30.6M.
Regeneron Pharmaceuticals made up 0.99% of Integral Health Asset Management's portfolio in Q2 2026, its #30 holding.
Integral Health Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
Integral Health Asset Management's Regeneron Pharmaceuticals position peaked at $81M in Q4 2025.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.